COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING is an esteemed journal published by Bentham Science Publishers Ltd, focusing on the rapidly evolving fields of combinatorial chemistry and high-throughput screening. With ISSN 1386-2073 and E-ISSN 1875-5402, this journal provides a critical platform for researchers, professionals, and students engaged in the development and application of novel methodologies aimed at drug discovery and organic chemistry. Since its inception in 1998, the journal has consistently contributed valuable insights, achieving a respectable 2023 Category Quartile Ranking of Q3 across relevant categories including Computer Science Applications, Drug Discovery, and Organic Chemistry. Although it does not currently provide open access options, its rigorous peer-review process and commitment to scientific excellence enhance its reputation in the academic community. Researchers can leverage this journal's findings to stay at the forefront of advancements in their fields, making it an essential resource for anyone dedicated to innovation in chemistry and related disciplines.

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

Journal of Natural Medicines, published by SPRINGER JAPAN KK, is a leading academic journal that plays a pivotal role in the advancement of research in the fields of Complementary and Alternative Medicine, Drug Discovery, Molecular Medicine, Organic Chemistry, and Pharmaceutical Science. Established in 1994 and set to continue until 2024, this journal serves as a vital conduit for the dissemination of groundbreaking research and innovative ideas that bridge traditional medicinal knowledge and modern scientific inquiry. With its impressive ranking in Scopus—ranking #12 out of 105 in Complementary and Alternative Medicine and holding a Q1 category quartile for 2023—it stands as a reputable source for high-quality, peer-reviewed articles. The journal's commitment to excellence is further underscored by its inclusion in the Springer network, providing researchers, professionals, and students with valuable insights and the latest developments in natural medicines. Although this journal operates under a subscription model, its profound impact on these interdisciplinary fields makes it an essential resource for anyone engaged in the study or practice of natural medicinal therapies.

PLANTA MEDICA is a premier journal dedicated to advancing the field of medicinal plant research, published by Georg Thieme Verlag KG in Germany. With an ISSN of 0032-0943 and an E-ISSN of 1439-0221, this journal has been a cornerstone of scholarly communication since its inception in 1961. Recognized for its rigorous peer-review process, PLANTA MEDICA holds a notable reputation in the academic landscape, featuring a 2023 Q2 ranking in categories such as Analytical Chemistry and Pharmaceutical Science, along with respectable Q3 rankings in Drug Discovery and Molecular Medicine. The journal focuses on the synthesis, pharmacological, and biochemical assessment of phytochemicals, making it an essential resource for researchers, professionals, and students alike who are engaged in the exploration of complementary and alternative medicine. Although it does not offer open access options, its content is instrumental in identifying new therapeutic agents derived from plants, thereby underscoring its importance in drug discovery and holistic health research.

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading journal in the fields of biochemistry, drug discovery, and medicinal chemistry, designed to disseminate significant advances in these disciplines. Established in 1991, the journal spans various important categories, including Organic Chemistry and Pharmaceutical Science, with its 2023 Scimago Journal Rank placing it at Q2 in Organic Chemistry and Q3 in several other relevant fields. Though not an open-access publication, it provides invaluable insights into contemporary research and innovative methodologies, appealing to researchers, professionals, and students alike. The journal's commitment to quality and relevance makes it a vital resource for those aiming to stay at the forefront of bioorganic and medicinal chemistry developments. For more information, please visit the journal's website as it remains a critical platform for scholarly exchange, particularly for those engaged in interdisciplinary research.

MINI-REVIEWS IN MEDICINAL CHEMISTRY is a distinguished journal published by Bentham Science Publishers, dedicated to the cutting-edge field of medicinal chemistry. With an ISSN of 1389-5575 and an E-ISSN of 1875-5607, this journal serves as an essential platform for researchers and professionals to disseminate concise yet comprehensive reviews that capture the latest advancements and trends in drug discovery, cancer research, pharmacology, and molecular medicine. Operating since 2001, it has consistently maintained a relevant presence in academia with its impressive rank metrics, including a Q2 category in Drug Discovery and Pharmacology in 2023, highlighting its significance in the scientific community. The journal is recognized for its rigorous peer-review process and provides an invaluable resource for students and researchers seeking insights into the rapidly evolving landscape of medicinal chemistry. With a commitment to excellence and innovation, MINI-REVIEWS IN MEDICINAL CHEMISTRY continues to foster knowledge exchange and inspire future breakthroughs in healthcare and therapeutic advancements.

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, published by Taylor & Francis Ltd, is a premier open-access journal that has been at the forefront of research in the field of medicinal chemistry since its inception in 1985. With an ISSN of 1475-6366 and an E-ISSN of 1475-6374, this journal boasts a prestigious reputation reflected in its impressive Q1 rankings across critical categories such as Drug Discovery and Pharmacology as of 2023. Situated in the United Kingdom, it plays a vital role in disseminating high-quality research that addresses the burgeoning needs of drug discovery and enzyme inhibition methodologies. The journal supports full open access, providing a platform for researchers, professionals, and students to share significant findings and innovations widely. With a robust impact factor, the JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY is indispensable for any academic or professional involved in the pharmacological sciences, offering an unparalleled insight into the latest advancements in therapeutic strategies and drug development.